Successful Management of Refractory Autoimmune Hemolytic Anemia with Cold Agglutinin Disease with Splenectomy: A Case Report with Review of Literature.
Autoimmune hemolytic anemia
Case report
Cold agglutinin disease
Splenectomy
Journal
The Kobe journal of medical sciences
ISSN: 1883-0498
Titre abrégé: Kobe J Med Sci
Pays: Japan
ID NLM: 0413531
Informations de publication
Date de publication:
11 Jan 2023
11 Jan 2023
Historique:
entrez:
16
1
2023
pubmed:
17
1
2023
medline:
19
1
2023
Statut:
epublish
Résumé
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by agglutination of red blood cells at temperatures below the normal core body temperature. In patients with CAD, splenectomy is not indicated because of its low therapeutic effect on hemolytic anemia induced by extravascular hemolysis. Herein, we report a case of refractory hemolytic anemia with CAD successfully managed with splenectomy. A 60-year-old man visited a municipal hospital with the chief complaint of fatigue. He was found to have hemolytic anemia and icterus with increased cold agglutination and was diagnosed with CAD. Malignant lymphoma was suspected as the underlying disease; however, no clear underlying disease was identified. Hemolytic anemia progressed during the subsequent winter seasons, and he was treated with temperature control, warming, and weekly blood transfusions. However, despite the blood transfusions, his hemoglobin level did not improve during the summer 2 years after diagnosis, and his previously observed splenomegaly had progressed. He was referred to our department, and a splenectomy was performed to diagnose any occult malignant lymphoma and improve the refractory hemolytic anemia. Because histopathological examination revealed no evidence of malignant lymphoma, a diagnosis of primary CAD was made. The hemolytic anemia improved, and no blood transfusion was required after splenectomy. Splenectomy significantly improved the patient's refractory hemolytic anemia due to primary CAD. Thus, it may be an effective treatment option in such cases, although further cases and studies are required to evaluate the effects of splenectomy.
Sections du résumé
BACKGROUND
BACKGROUND
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by agglutination of red blood cells at temperatures below the normal core body temperature. In patients with CAD, splenectomy is not indicated because of its low therapeutic effect on hemolytic anemia induced by extravascular hemolysis. Herein, we report a case of refractory hemolytic anemia with CAD successfully managed with splenectomy.
CLINICAL CASE
METHODS
A 60-year-old man visited a municipal hospital with the chief complaint of fatigue. He was found to have hemolytic anemia and icterus with increased cold agglutination and was diagnosed with CAD. Malignant lymphoma was suspected as the underlying disease; however, no clear underlying disease was identified. Hemolytic anemia progressed during the subsequent winter seasons, and he was treated with temperature control, warming, and weekly blood transfusions. However, despite the blood transfusions, his hemoglobin level did not improve during the summer 2 years after diagnosis, and his previously observed splenomegaly had progressed. He was referred to our department, and a splenectomy was performed to diagnose any occult malignant lymphoma and improve the refractory hemolytic anemia. Because histopathological examination revealed no evidence of malignant lymphoma, a diagnosis of primary CAD was made. The hemolytic anemia improved, and no blood transfusion was required after splenectomy.
CONCLUSIONS
CONCLUSIONS
Splenectomy significantly improved the patient's refractory hemolytic anemia due to primary CAD. Thus, it may be an effective treatment option in such cases, although further cases and studies are required to evaluate the effects of splenectomy.
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E30-E34Références
Hematol Oncol Stem Cell Ther. 2022 Dec 23;15(4):213-216
pubmed: 32645300
Vox Sang. 1985;48(2):105-9
pubmed: 4072091
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):226-231
pubmed: 27913484
Sci Rep. 2020 Jul 29;10(1):12694
pubmed: 32728060
Ann Intern Med. 1987 Feb;106(2):238-42
pubmed: 3800184
Front Immunol. 2020 Jun 03;11:946
pubmed: 32655543
Blood. 2017 Jul 27;130(4):537-541
pubmed: 28533306
Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1599-608
pubmed: 25154254
Hematology. 2007 Oct;12(5):361-70
pubmed: 17891600
Blood. 2013 Aug 15;122(7):1114-21
pubmed: 23757733
Blood Rev. 2012 May;26(3):107-15
pubmed: 22330255
Front Immunol. 2020 Apr 07;11:590
pubmed: 32318071
N Engl J Med. 1977 Jun 30;296(26):1490-4
pubmed: 865527
J Blood Med. 2019 Apr 09;10:93-103
pubmed: 31114413
Haematologica. 2014 Oct;99(10):1547-54
pubmed: 25271314
Haematologica. 2006 Apr;91(4):460-6
pubmed: 16585012